Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype-Reference-Cited by-同舟云学术

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

Published:2009-11-08 Issue:1 Volume:16 Page:49-58
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Starczynowski Daniel T,Kuchenbauer Florian,Argiropoulos Bob,Sung Sandy,Morin Ryan,Muranyi Andrew,Hirst Martin,Hogge Donna,Marra Marco,Wells Richard A,Buckstein Rena,Lam Wan,Humphries R Keith,Karsan Aly

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2054.pdf

Reference49 articles.

1. Corey, S.J. et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer 7, 118–129 (2007).

2. Nilsson, L. et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q–deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96, 2012–2021 (2000).

3. Nilsson, L. et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 110, 3005–3014 (2007).

4. Thanopoulou, E. et al. Engraftment of NOD/SCID-β2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 103, 4285–4293 (2004).

5. Nimer, S.D. Myelodysplastic syndromes. Blood 111, 4841–4851 (2008).

Cited by 558 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia;Biochemistry and Cell Biology;2023-12-01

2. Protocol for performing consecutive bone marrow transplants in mice to study the role of marrow niche in supporting hematopoiesis;STAR Protocols;2023-12

3. ABIN1 (Q478) is Required to Prevent Hematopoietic Deficiencies through Regulating Type I IFNs Expression;Advanced Science;2023-11-27

4. Physiopathologie des syndromes myélodysplasiques;Bulletin du Cancer;2023-11

5. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies;Frontiers in Immunology;2023-10-26